Clinical trial
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults…
NCT06716606 · GlaxoSmithKline, Industry · Recruiting
Key facts
| NCT number | NCT06716606 |
|---|---|
| Title | A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE) |
| Official title | An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Collaborators | ICON plc Industry |
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Connective Tissue Diseases |
| Intervention type | Drug |
| Interventions | Belimumab |
| Enrollment | 514 |
| Start date | Dec 12, 2024 |
| Primary completion | Dec 27, 2029 |
| Completion | Dec 27, 2029 |
| First posted | Dec 4, 2024 |
| Last update posted | Dec 9, 2025 |
| Countries | Argentina, China, Greece, Japan, South Korea, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: